Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

BrightGene Pharmaceutical Co., Ltd., an international, innovation-driven pharmaceutical company, presented data from two Phase 2 studies for BGM0504, its ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

Wegovy, to be in pharmacies by the end of June, has been launched in a pen-injection format with strengths ranging from 0.25 ...

Though the medication cannot actually increase the size of your bits, it can improve your blood flow and reduce the amount of ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable ...

VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce the launch of a feasibility study for the ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...